NCT05993299: Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma |
|
|
| Active, not recruiting | 2 | 7 | Europe, Canada, US | Letetresgene autoleucel, Cyclophosphamide, Fludarabine | Adaptimmune | Neoplasms | 10/22 | 07/25 | | |
| Active, not recruiting | 2 | 103 | Europe, Canada, US | Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide | Adaptimmune | Neoplasms | 09/24 | 07/26 | | |
2018-003949-42: A study of NY-ESO-1 T-cells (GSK3377794) alone and in combination with Pembrolizumab in NSCLC patients. |
|
|
| Not yet recruiting | 1/2 | 54 | Europe | GSK3377794, Pembrolizumab, GSK3377794, MK-3475, Dispersion for infusion, Solution for infusion, KEYTRUDA | GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A., GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A. | Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Cancer (NSCLC), Diseases [C] - Cancer [C04] | | | | |